8:00 am Chair’s Opening Remarks

Approaching Neuroinflammation as a Therapeutic Target for Neurodegenerative Diseases

8:15 am The Interface of Inflammation & Cell Death: Disease Progression in Multiple Sclerosis & Beyond

Synopsis

• RIPK1 as a key node in regulating cell death and inflammation
• An inflammatory CNS environment that leads to disease progression in MS
• Targeting CNS inflammation in MS and other neurodegenerative diseases

8:45 am Microglia: Suppress or Promote?

Synopsis

• When should neurotoxic neuroinflammation be suppressed and when should
protective immune response be promoted?
• Considering time of therapeutic intervention and disease state
• Eliminating microglia from the brain: microglial repopulation

9:15 am Assessment of Antibody Profiling in Neurodegenerative Disease

Synopsis

• Bringing together cutting-edge technologies including antibody repertoire
profiling and deep learning for neuroimmunology drug development
• Further talk details to follow

9:45 am Speed Networking

Synopsis

This session is the ideal opportunity to meet face-to-face with the key thought
leaders working in the neuroimmunology field. Specifically designed to connect you
with new contacts from the most active companies in the field, the renowned Speed
Networking session will be one of the most valuable hours you will spend at the
Neuroimmunology Drug Development Summit.

10:30 am Morning Refreshments

Identifying Translational Biomarkers to Effectively Translate into the Clinic

11:30 am From Animal to Man: Building Target Engagement to Proof of Concept Pathway

  • Johan Luthman Executive Vice President, Research & Development, Lundbeck

Synopsis

• Neuroimmunology/neuroinflammation opportunities for translational tools,
preclinical models and biomarkers in human models
• Possibilities for target engagement evaluation for neuroimmune/
neuroinflammation targets in the brain
• How do we de-risk the clinical program through proof of principle and proof of
concept studies?

12:00 pm Stabbing in the Dark: Biomarkers of Microglial Pathway Activation

Synopsis

• Exploring biomarker data from neuroimmunology mouse studies
• Bridging the gap: From mouse to NHP

12:30 pm The Challenge of Developing Translatable Biomarkers to Guide the Clinical Interrogation of LRRK2 Kinase Inhibitors for Parkinson’s Disease

  • Matthew Fell Principal Scientist, Neuroimmunology, Merck Research Laboratories

Synopsis

• Developing potent, selective and brain penetrant inhibitors of LRRK2 kinase
activity
• Leveraging PBMC biomarkers to assess CNS target engagement in the clinic
• Developing CSF biomarkers of central LRRK2 kinase activity

1:00 pm Lunch & Networking

Utilizing Technology Advances to Better Understand the Neuroimmune System

2:00 pm Single Cell Sequencing & Spatial Transcriptomic Approaches to Characterize Human Cells & Tissues

  • Rebecca Mathew Senior Scientist, GpGx-Genome Sciences, Merck Research Laboratories

Synopsis

• Transcriptomics studies have revealed that freshly isolated human microglia cells
rapidly lose their identity when sub-cultured in vitro
• Spatial transcriptomics (ST) is a new technology that provides a region-specific
map of gene expression from in-tact tissue sections
• ST can define transcriptional states of human microglia without destruction of the
tissue microenvironment

2:30 pm Moving Away from Microglial Targets & Appreciating Astrocyte Contribution

Synopsis

• Astrocytes have been overlooked in drug discovery
• Astrocytic processes are fundamental to CNS homeostasis, and their dysfunction is
both a consequence and cause of neurodegeneration
• Astrocytes are potentially an untapped source of new targets for
neurodegenerative disease

3:00 pm Exploring Nuclear Imaging Approaches to Understand & Monitor Neuroinflammation

Synopsis

• TSPO imaging and its limitations
• Current efforts to image alternative aspects of neuroinflammation including
P2X7R, CSF1R, COX2 and ROS.
• Pre-targeting Imaging and utilization of large molecules to monitor
neuroinflammation

3:30 pm Afternoon Refreshments & Networking

Connecting Neuroinflammation to Human Patients

4:00 pm The Role of Microglial BIN1 in Alzheimer’s Disease: From Genetics to Target Validation

Synopsis

• GWAS hits in BIN1 locus affect BIN1 expression specifically in microglia and
positively correlate with tau-PET in Alzheimer’s Disease-affected individuals
• BIN1-associated tau-containing extracellular vesicles purified from Cerebrospinal
Fluid (CSF) of Alzheimer’s Disease-affected individuals are seeding-competent
• Genetic deletion of Bin1 from microglia resulted in reduction of tau secretion via
extracellular vesicles in vitro, and in decrease of tau spreading in vivo

4:30 pm Panel Discussion: Are We Chasing the Wrong Phenomenon?

  • Malu Tansey Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center, The University of Florida College of Medicine
  • Richard Ransohoff Venture Partner, Third Rock Ventures

Synopsis

• Do we have clinical proof of neuroinflammation as an effective target for neurodegeneration? Improving target
identification logic: is neuroinflammation a cause or outcome?
• Debating Biogen’s aducanumab implications on neuroinflammatory targets – standalone treatment or an add on?
• Where are the challenges in neurodegeneration/neuroinflammation drug development compared to other disease
areas like cardiovascular?
• How do we intervene with the neuroimmune system beyond genetic targets?

5:00 pm Chair’s Closing Remarks

5:15 pm Scientific Poster Session

Synopsis

The learning and networking continues at the Poster Session, an informal part
of the conference agenda, allowing you to connect with your peers in a relaxed
atmosphere and continue to forge new, beneficial relationships. You will have the
opportunity to present and review presentations displaying new data and the latest
advances in neuroimmunology drug development research.